Immunomodulatory effect of sertraline in a rat model of rheumatoid arthritis

NeuroImmunoModulation

Volumn 19, Issue 5, 2012, Pages 309-318

  Baharav, Ehud ^a,d   Bar, Meytal ^b,d   Taler, Michal ^b,d   Gil Ad, Irit ^b,d   Karp, Leon ^c   Weinberger, Abraham ^a,d   Weizman, Avraham ^b,c,d  

^a RABIN MEDICAL CENTER   (Israel)

^b Laboratory of Biological Psychiatry   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adjuvant arthritis; Cytokines; Depression; Immunomodulation; Inflammation; Rheumatoid arthritis; Sertraline

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOMODULATING AGENT; INTERLEUKIN 10; METHOTREXATE; PARACETAMOL; SERTRALINE; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRALGIA; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME SYNTHESIS; FEMALE; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SPLEEN CELL;

ANALYSIS OF VARIANCE; ANIMALS; ARTHRITIS, RHEUMATOID; CONCANAVALIN A; CYCLOOXYGENASE 2; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DISABILITY EVALUATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FREUND'S ADJUVANT; IMMUNOLOGIC FACTORS; METHOTREXATE; RATS; RATS, INBRED LEW; SERTRALINE; SPLEEN; THYMIDINE;

EID: 84863759331     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000339109     Document Type: Article

References (52)

1. Maes M: Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1955; 19: 11-38.
2. Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR: Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(suppl 5):899-905.
3. Corcos M, Guilbaud O, Hjalmarsson L, Chambry J, Jeammet P: Cytokines and depression: an analogic approach. Biomed Pharmacother 2002; 56(suppl2):105-110. (Pubitemid 34241566)
4. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kre-mers LHM, Mayes MD, Merke PA, Pillemer SR, Reveille JD, Stone JH: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58(suppl 1):15-25.
5. Keffer J, Probert L, Cazlaris H, Georgopou-los S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10:4025-4031. (Pubitemid 21905432)
6. Cvetkovic JT, Wallberg-Jonsson S, Stegmayr B, Rantapaa-Dahlqvist S, Lefvert AK: Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-a, IL-1ß, and IL-1Ra genes. J Rheumatol 2002; 29: 212-219. (Pubitemid 34118764)
7. Covic T, Pallant JF, Tennant A, Cox S, Emery P, Conaghan PG: Variability in depression prevalence in early rheumatoid arthritis: a comparison of the CES-D and HAD-D Scales. BMC Musculoskelet Disord 2009; 10: 18.
8. Dickens C, McGowan L, Clark-Carter D, Creed F: Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med 2002; 64(suppl 1):52-60. (Pubitemid 34137399)
9. Wolfe F, Michaud K: Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity. Arthritis Care Res 2009; 61:667-673.
10. Ang DC, Choi H, Kroenke K, Wolfe F: Co-morbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol 2005; 32:1013-1019. (Pubitemid 40828071)
11. Nemeroff CB: The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res 2007; 41:189-206. (Pubitemid 44854991)
12. Stafford RS, MacDonald EA, Finkelstein SN: National patterns of medication treatment for depression, 1987 to 2001. Primary Care Companion J Clin Psychiatry 2001; 3(suppl 6):232-235. (Pubitemid 33807565)
13. Anderson GM, Bennett AJ, Weld KP, Push-kas JG, Ocame DM, Higley JD: Serotonin in cisternal cerebrospinal fluid of rhesus monkeys: basal levels and effects of sertraline administration. Psychopharmacology (Berl) 2002; 161(suppl 1):95-99. (Pubitemid 34437974)
14. Ptak W, Geba GP, Askenase PW: Initiation of delayed-type hypersensitivity by low doses of monoclonal IgE antibody. Mediation by serotonin and inhibition by histamine. J Immunol 1991; 146:3929-3936.
15. Hellstrand K, Hermodsson S: Enhancement of human natural killer cell cytotoxicity by serotonin: role of non-T/CD16+ NK cells, accessory monocytes, and 5HT1A receptors. Cell Immunol 1990; 127: 199-214. (Pubitemid 20119676)
16. 1A receptors. Cell Immunol 1995; 163: 1-9.
17. Arzt E, Costas M, Finkielman S, Nahmod VE: Serotonin inhibition of tumour necrosis factor-a synthesis by human monocytes. Life Sci 1991; 48:2557-2562.
18. Mossner R, Lesch KP: Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun 1998; 12: 249-271. (Pubitemid 29224829)
19. 1B receptors activation is regulated by 5-HT-moduline. CR Acad Sci III 2001; 324: 365-372. (Pubitemid 32401270)
20. Perrot S, Javier RM, Marty M, Le Jeunne C, Laroche F: Is there any evidence to support the use of anti-depressants in painful rheu-matological conditions? Systematic review of pharmacological and clinical studies. Rheumatology (Oxford) 2008; 47(suppl 8):1117-1123. (Pubitemid 352038213)
21. Abdel-Salam OM, Baiuomy AR, Arbid MS: Studies on the anti-inflammatory effect of fluoxetine in the rat. Pharmacol Res 2004; 49(suppl2):119-131. (Pubitemid 37485709)
22. Kubera M, Cyrul W, Basta-Kaim A, Budziszewska B, Leskiewicz M, Holan V: Effect of repeated desipramine and fluoxetine administration on post-adjuvant arthritis. Pol J Pharmacol 2000; 52(suppl 3):229-235. (Pubitemid 30479573)
23. Kling A, Danell-Boman M, Stenlund H, Dahlqvist R: Association between the use of serotonin receptor 2A-blocking antidepressants and joint disorders. Arthritis Rheum 2009; 61:1322-1327.
24. Harbuz MS, Marti O, Lightman SL, Jessop DS: Alteration of central serotonin modifies onset and severity of adjuvant-induced arthritis in the rat. Br J Rheumatol 1998; 37(suppl 10):1077-1083.
25. Parker JC, Smarr KL, Slaughter JR, Johnston SK, Priesmeyer ML, Hanson KD, Johnson GE, Hewett JE, Hewett JE, Irvin WS, Koma-tireddy GR, Walker SE: Management of depression in rheumatoid arthritis: a combined pharmacologic and cognitive-behavioral approach. Arthritis Rheum 2003; 49(suppl 6):766-777. (Pubitemid 37523628)
26. Taler M, Bar M, Korob I, Lomnitski L, Baha-rav E, Grunbaum-Novak N, Weizman A, Gil-Ad I: Evidence for an inhibitory immu-nomodulatory effect of selected antidepres-sants on rat splenocytes: possible relevance to depression and hyperactive-immune disorders. Int Immunopharmacol 2008; 8(suppl 4):526-533.
27. Whitehouse MW: Adjuvant arthritis 50 years on: the impact of the 1956 article by C. M. Pearson, Development of arthritis, periarthritis and periostitis in rats given adjuvants. Inf lamm Res 2007; 56(suppl 4):133-138.
28. Pearson CM: Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 2006; 91: 95-101.
29. Culigan TE, Krinsbeek AM, Margulis DH, Sherach EM, Strober W: Adjuvant arthritis in the rat; in: Current Protocols in Immunology. New York, Wiley, 1996, pp 15.4.1-15.4.7 (suppl 19).
30. Taler M, Gil-Ad I, Lomnitski L, Korov I, Ba-harav E, Bar M, Zolokov A, Weizman A: Im-munomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol 2007; 17(suppl 12):774-780. (Pubitemid 47588862)
31. O'Brien SM, Scott LV, Dinan TG: Antide-pressant therapy and C-reactive protein levels. Br J Psychiatr y 2006; 188: 449-452.
32. Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O, Sanisoglu SY, Yesilova Z, Ozmenler N, Ozsahin A, Sengul A: Pro-and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007; 763-796.
33. Onat AM, Oztürk MA, Ozçakar L, Ureten K, Kaymak SU, Kiraz S, Ertenli I, Calgüneri M: Selective serotonin reuptake inhibitors reduce the attack frequency in familial Mediterranean fever. Tohoku J Exp Med 2007; 211(suppl 1):9-14. (Pubitemid 46062215)
34. Sacre S, Medghalchi M, Gregory B, Brennan F, Williams R: Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis R heum 2010; 62: 683-693.
35. Vollmar P, Nessler S, Kalluri SR, Hartung HP, Hemmer B: The antidepressant venla-faxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int J Neuro-psychopharmacol 2009; 12(suppl 4):525-536.
36. Kiely PDW, Brown AK, Edwards CJ, O'Reilly DT, Östör AJK, Quinn M, Taggart A, Taylor PC, Wakefield RJ, Conaghan PG: Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology 2009; 48:765-772.
37. Guo JP, Bäckdahl L, Marta M, Mathsson L, Rönnelid J, Lorentzen JC: Profound and paradoxical impact on arthritis and autoimmu-nity of the rat antigen-presenting lectin-like receptor complex. Arthritis Rheum 2008; 58(suppl 5):1343-1353. (Pubitemid 351705924)
38. Weiss RJ, Erlandsson Harris H, Palmblad K: Highly arthritis-susceptible DA rats express IL-1beta in articular cartilage. Scand J Immunol 2009; 69(suppl 3):188-193.
39. 3 receptor subtypes in serum-free tissue culture of mac-rophage-like synovial cells. Rheumatol Int 2008; 28:1017-1022.
40. Faerber L, Drechsler S, Ladenburger S, Gschaidmeier H, Fischer W: The neuronal 5-HT3 receptor network after 20 years of research-evolving concepts in management of pain and inflammation. Eur J Pharmacol 2007;560:1-8.
41. Bischoff SC, Mailer R, Pabst O, Weier G, Sed-lik W, Li Z, Chen JJ, Murphy DL, Gershon MD: Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitroben-zene sulfonic acid colitis in mice. Am J Physi-ol Gastrointest Liver Physiol 2009; 296(suppl 3):G685-G695.
42. Kopp S, Alstergren P: Blood serotonin and joint pain in seropositive versus seronegative rheumatoid arthritis. Mediators Inflamm 2002; 11(suppl 4):211-217. (Pubitemid 35155463)
43. Pellegrino TC, Bayer BM: Specific serotonin reuptake inhibitor-induced decreases in lymphocyte activity require endogenous serotonin release. Neuroimmunomodulation 2000; 8(suppl 4):179-187. (Pubitemid 32225752)
44. Evans DM, Zhu G, Duffy DL, Frazer IH, Montgomery GW, Martin NG: A major quantitative trait locus for CD4-CD8 ratio is located on chromosome 11. Genes Immun 2004; 5(suppl 7):548-552. (Pubitemid 39529971)
45. Fazzinoa F, Urbinaa M, Cedeñoa N, Lima L: Fluoxetine treatment to rats modifies serotonin transporter and cAMP in lymphocytes, CD4+ and CD8+ subpopulations and interleukins 2 and 4. Int Immunopharmacol 2009; 9(suppl 4):463-467.
46. Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D: Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hy-aluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum 1999; 42(suppl 12):2561-2568. (Pubitemid 30327172)
47. Slaughter JR, Parker JC, Martens MP, Smarr KL, Hewett JE: Clinical outcomes following a trial of sertraline in rheumatoid arthritis. Psychosomatics 2002; 43(suppl 1):36-41. (Pubitemid 34214160)
48. Michaud K, Wolfe F: Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheu-matol 2007; 21(suppl 5):885-906. (Pubitemid 47377810)
49. Low CA, Cunningham AL, Kao AH, Krish-naswami S, Kuller LH, Wasko MC: Association between C-reactive protein and depressive symptoms in women with rheumatoid arthritis. Biol Psychol 2009; 81(suppl 2): 131-134.
50. Zazpe A, Artaiz I, Labeaga L, Lucero ML, Orjales A: Reversal of learned helplessness by selective serotonin reuptake inhibitors in rats is not dependent on 5-HT availability. Neuropharmacology 2007; 52(suppl 3):975-984. (Pubitemid 46227484)
51. Pinna G, Costa E, Guidotti A: Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology (Berl) 2006; 186 (suppl 3):362-372. (Pubitemid 43800838)
52. Di Santo E, Foddi MC, Ricciardi-Castagnoli P, Mennini T, Ghezzi P: DHEAS inhibits TNF production in monocytes, astrocytes and microglial cells. Neuroimmunomodula-tion 1996; 3(suppl 5):285-288. (Pubitemid 27230989)